REGN

Regeneron Pharmaceuticals, Inc. - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2001. Regeneron is a biopharmaceutical company focused on discovering and developing therapeutic drugs for serious medical conditions. The company has not yet generated sales or profits from the commercialization of its product candidates and relies on collaboration agreements, equity offerings, and investment income to fund operations.

Key Financial Metrics

Note: Total liquid assets include Cash, Cash Equivalents, and Marketable Securities.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased significantly due to a reduction in contract research and development revenue. Payments from The Procter & Gamble Company decreased to $2.5 million per quarter in 2001 from $7.1 million in 2000. Additionally, revenue from Amgen-Regeneron Partners dropped following the discontinuation of BDNF clinical trials in January 2001.
• Expense Increase: Operating expenses rose to $23.9 million in Q2 2001 from $18.4 million in Q2 2000. Research and development expenses increased to $19.6 million, driven by higher staffing and expanded clinical/preclinical activities.
• Liquidity Improvement: Cash and cash equivalents increased from $31.0 million at year-end 2000 to $143.0 million at June 30, 2001. This was primarily driven by a public offering in March 2001 that raised approximately $153.6 million in net proceeds.
• Accounting Change: The company adopted Staff Accounting Bulletin 101 (SAB 101) effective January 1, 2000, resulting in a cumulative effect adjustment that increased net loss by $1.6 million in the prior period.

Outlook, Risks, and Management Commentary

• Clinical Pipeline: Regeneron initiated a Phase III program for AXOKINE (obesity treatment) in July 2001, enrolling approximately 2,000 patients. Other programs include IL-1 Trap (rheumatoid arthritis), IL-4/IL-13 Trap (asthma), and VEGF Trap (cancer), with Phase I trials expected in late 2001 or mid-2001.
• Capital Resources: Management believes existing capital resources ($290.5 million in cash and marketable securities) will fund operations through at least 2002. Approximately 50-70% of expenditures are expected to be directed toward preclinical and clinical development.
• Risks: Key risks include the failure of clinical trials, the development of neutralizing antibodies to protein therapies, delays in regulatory approval, and the potential termination of collaboration agreements (specifically with Procter & Gamble and Amgen). The company also faces a patent opposition challenge from Immunex Corporation regarding its Cytokine Traps patent.
• Unusual Items: The loss in Amgen-Regeneron Partners decreased due to the cessation of BDNF development. The company recognized a cumulative effect of $1.6 million related to the adoption of SAB 101 in the prior year.

Investor Verification Checklist

• Collaboration Terms: Verify the specific terms and duration of the new Procter & Gamble agreement effective December 31, 2000, and the impact of the reduced quarterly funding on future cash flow.
• Phase III Trial Progress: Monitor enrollment rates and interim data for the AXOKINE Phase III obesity trial initiated in July 2001.
• Patent Litigation: Track the status of the European Patent Office opposition filed by Immunex Corporation regarding the Cytokine Traps patent.
• Burn Rate: Assess the sustainability of the current operating loss trajectory ($27.9 million for six months) against the $290.5 million cash balance to confirm the runway through 2002.
• Amgen Partnership: Review the future capital contribution requirements for Amgen-Regeneron Partners following the discontinuation of BDNF and the ongoing evaluation of NT-3.